In R&D rethink, Novartis ditches part of $2.6B Xencor bispecific pact

Citing “strategic pipeline reprioritization by Novartis,” Xencor says its Swiss Big Pharma partner is handing back the research and sales rights to a bispecific antibody penned under a multibillion-dollar biobucks deal in 2016.